



Date: 28 October 2019

Sydney, Australia

ASX Limited
20 Bridge Street
SYDNEY NSW 2000

Dr Graham Kelly to Assume CEO Role

- Graham Kelly, Founder of Noxopharm, to resume Interim CEO role while also maintaining his position as Executive Chairman
 - Leadership requirement coincides with planned significant corporate growth including proposed dual listing of the Company
-

Sydney, 28 October 2019: Noxopharm (ASX: NOX) announces that Dr Graham Kelly will assume the duties of interim CEO following the departure of former CEO, Dr Greg van Wyk.

While the Board understands that a dual CEO/Chairman is not optimal, it proposes to appoint an Australian-based senior executive with a strong financial and business background to assist Dr Kelly in what is anticipated to be a period of strong corporate and business growth. The corporate growth is expected to come from a proposed dual listing and emerging opportunities for business development. The business growth is expected to be driven by the decision to accelerate the development of Veyonda[®], based on strongly positive clinical signals in the DARRT-1 clinical study.

Dr Kelly will remain as Executive Chairman on an annual salary of \$300,000 for the dual roles. The Board believes that Dr Kelly is ideally suited to advancing the Company's strategic agenda as an Interim CEO at this critical phase of its development. The dual role is interim while the Company undertakes a search for a new CEO in 2020. Dr Kelly's role as chair is more long-term.

Dr Kelly brings to the role:

- his extensive corporate knowledge of Veyonda[®]
- his experience in founding and overseeing the growth of 3 public biotech companies
- his experience in having listed two companies on the Nasdaq exchange.

Mr Greg Ambra, recently appointed as Senior Vice-President North American Operations, will play a key role in assisting Dr Kelly in growing the Company's presence and profile in the U.S.

**About Noxopharm**

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in Nyrada Inc, a spin-off company developing a pipeline of non-oncology drugs.

www.noxopharm.com

Investor & Corporate Enquiries**Media Contact Australia**

Prue Kelly

M: 0459 022 445

E: Prue.Kelly@noxopharm.com

Company Secretary:

David Franks

T: +61 2 9299 9690

E: David.Franks@atomicgroup.com.au

Media Contact USA:

Frank de Maria

Purposeful Communications

T: +1 347 647 0284

E: frank.demaria@purposefulcommunications.com

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.